Posted on

MINDCURE to Present at the Benzinga Healthcare Small Cap Conference

MINDCURE to Present at the Benzinga Healthcare Small Cap Conference

VANCOUVER,BC, September28, 2021 /CNW/ – MindCure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH)(“MINDCURE” or the “Company”), a leader inadvanced proprietary technology and research in psychedelics, today announcedthat Kelsey Ramsden, President & CEO of MINDCURE, will present at the BenzingaHealthcare Small Cap Conference, which is being held virtually on September29-30, 2021. Investors can register for the conference here.

In addition, Ms. Ramsden will participate inone-on-one investor meetings during the conference. To schedule a one-on-onemeeting, please contact KCSA Strategic Communications at MindCure@kcsa.com.  

Benzinga Healthcare Small Cap Conference Presentation

Date: Wednesday,September 29, 2021

Time: 4:00 pm ET

Speaker: Kelsey Ramsden, President & CEO of MINDCURE

Link: Healthcare:September 29-30 – Benzinga Small Cap Conference

In other news, the Company also announces ithas granted a total of 10,000 stock options to certain employees pursuant tothe terms the Company’s long term incentive plan (“Plan”). The stock optionsare exercisable at a price of $0.34 per share, and are subject to the terms ofthe Plan. The Company further announces it has issued 59,296 common shares to aconsultant at an agreed-upon price of $0.38 per share.

About Mind Cure Health Inc.

MINDCURE is a life sciencescompany focused on innovating and commercializing new ways to promote healingand improve mental health. The Company is developing digital therapeuticstechnology and researching psychedelic compounds to support access to safe, evidence-basedpsychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board ofDirectors
KelseyRamsden, President & CEO
Phone:1-888-593-8995

Forward-Looking Information

Certaininformation presented in this news release may constitute “forward-lookinginformation” within the meaning of applicable securities laws regardingMINDCURE and its business. Forward-looking information generally can beidentified by the use of terms and phrases such as “anticipate”,”believe”, “could”, “estimate”,”expect”, “feel”, “intend”, “may”,”plan”, “predict”, “project”, “subjectto”, “will”, “would”, and similar terms and phrases.

Forward-lookinginformation is based on a number of key expectations and assumptions made bymanagement of MINDCURE, including, without limitation: the COVID-19 pandemicimpact on the Canadian economy and MINDCURE’s business, and the extent andduration of such impact; no change to laws or regulations that negativelyaffect MINDCURE’s business; there will be a demand for MINDCURE’s products inthe future; no unanticipated expenses or costs arise; MINDCURE will be able tocontinue to identify products that make them ideal candidates for providingsolutions for treating mental health; and that MINDCURE will advance wellnessworldwide.

Forward-lookinginformation is provided for the purpose of presenting information aboutmanagement’s current expectations and plans relating to the future and readersare cautioned that such statements may not be appropriate for other purposes.Forward-looking information inherently entails known and unknown risks anduncertainties about the future and actual results, and involves significantrisks and uncertainties and should not be read as a guarantee of futureperformance or results as actual results may differ materially from thoseexpressed or implied in such forward-looking information. Although MINDCURE hasattempted to identify important factors that could cause actual results,performance or achievements to differ materially from those described in forward-lookinginformation presented, there may be other factors that cause results,performance or achievements to differ from those anticipated, estimated orintended. Accordingly, readers should not place undue reliance on anyforward-looking statements as no forward-looking information can be guaranteed.

Except asrequired by applicable securities laws, forward-looking statements speak onlyas of the date on which they are made and MINDCURE does not undertake anyobligation to publicly update or revise any forward-looking information,whether as a result of new information, future events, or otherwise.

SOURCE Mind Cure Health Inc.

For further information:  

MINDCURE Investor Relations

investors@mindcure.com

1-888-593-8995

Media Inquiries

Annie Graf / Kristin Cwalinski

KCSA Strategic Communications

mindcure@kcsa.com

Posted on

AIkido Pharma Secures Interest in Electric Truck Maker, Tevva Motors Ltd

AIkido Pharma Secures Interest in Electric Truck Maker, Tevva Motors Ltd

PR Newswire

NEW YORK , Sept. 28, 2021 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company secured an equity interest in Tevva Motors Ltd , an electric truck producer with range extended vehicles on the road now.

 

Tevva Motors Ltd is a UK-based, leading developer of modular electrification systems for medium duty commercial vehicles. Using a system engineering approach, Tevva has developed world-class electric vehicle technology that adheres to the most rigorous of standards to ensure safety, reliability and durability. Tevva’s core proprietary technologies – comprising battery pack and management system, control system, software, and optional range extender – are applicable to almost any current 7.5t – 14t truck and is supplied as a package to OEMs for integration with their vehicles.

Anthony Hayes , CEO of AIkido, noted, “From a commercial standpoint, delivery trucks are a $100 billion global market and demand for a cost effective, zero emission solution is growing by the day. With strategic partners and early customers including, Ryder, Hitachi and UPS, and with Tevva vehicles already being used in their delivery services, Tevva is well positioned to take advantage of this rapidly growing sector.”  Mr. Hayes went on to state, this unique and high growth opportunity represents an opportunity to partake in a rapidly expanding field, with the possibility of an exit in early 2022 as Tevva pursues a public listing.  As we continue to focus on our core business, which is drug development.  However, in our search for opportunities in our space, this unique growth opportunities with strong likelihood for monetization events, was presented to us.  We are always looking to create shareholder value while limiting exposure in exciting and growing industries.  We hope this short-term opportunity becomes an asset for our shareholders, like DatChat.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas , Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

CisionView original content to download multimedia: https://www.prnewswire.com/news-releases/aikido-pharma-secures-interest-in-electric-truck-maker-tevva-motors-ltd-301386841.html

SOURCE AIkido Pharma Inc.

News Provided by PR Newswire via QuoteMedia

Posted on

NeonMind Advances Strategy For Specialty Clinic Launch

NeonMind Advances Strategy For Specialty Clinic Launch

Company expects to launch first specialty clinic locations by early 2022

 NeonMind-branded specialty mental health clinics to bring innovative interventional psychiatry treatments to underserved populations in Canada

 Vancouver, B.C. – September 28, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, today provided an update on the Company’s medical services division, including its specialty clinics initiative to establish a national network of clinics offering interventional psychiatry treatments. The Company recently established a best-in-class Specialty Clinics Advisory Board to oversee the advancement of its medical services division and is currently in advanced negotiations with potential partners to launch locations in early 2022.

 

Specialty Mental Health Clinics Update

To continue its commitment in providing access to psychedelic-based treatments for mental health disorders, NeonMind is working to establish NeonMind-branded specialty mental health clinics. The Company is in ongoing discussions with a number of key opinion leaders and potential strategic partners, all of which are progressing successfully and are currently in late-stage assessments.

Based on the progress to-date, NeonMind expects its first clinic to go live by early 2022. Following the first clinic opening, the Company anticipates the launch of additional clinic locations throughout the course of 2022, continuing to expand locations and services in 2023 and beyond.

“We continue to be encouraged by the clinical promise and market potential for interventional psychiatry,” said Rob Tessarolo, President and CEO of NeonMind. “There is unprecedented demand for these innovative treatments and we have an opportunity to be the first major player in this space. We continue to have late stage discussions as we evaluate a series of potential opportunities and partnerships, which we believe will be transformational for NeonMind and the patients we aim to serve.”

Mr. Tessarolo added, “Our discussions are focused on operational partners with a proven track record of success in the medical treatment space to operate our national clinic network in a capital efficient manner. We are encouraged by the reception we have received and look forward to providing further updates as these discussions continue to advance.”

 

Strategic Opportunity in Interventional Psychiatry – Addressing a Major Medical Market

Mental health disorders have reached a crisis level, which has been compounded by the effects of the COVID-19 pandemic, in particular, depression and anxiety disorders.  The economic burden is massive with an estimated cost of $51 billion annually to Canadians1. Traditional treatments such as pharmacotherapy and psychotherapy have varying degrees of effectiveness, but for the most part leave the crisis largely unaddressed.

A new and promising field of interventional psychiatry including ketamine/esketamine, neurostimulation, and psychedelic treatment modalities are showing unprecedented clinical efficacy. This new modality is establishing itself as a game changing and staple armamentarium for patients and clinicians.  Despite this, broader access to these treatments remains extremely limited in Canada due to a lack of infrastructure and awareness.

Importantly, these treatments require specialized clinic models and treatment teams which is the focus of NeonMind’s medical services division: to establish NeonMind-branded, best-in-class, national specialty clinics network providing interventional psychiatry treatments tailored for local communities’ healthcare needs.

Strategically, NeonMind’s near-term focus is to scale its services to address the large demand for clinician-validated treatments including ketamine/esketamine and neurostimulation.  With impending regulatory approvals for psychedelic modalities including MDMA for anxiety disorders, psilocybin for depression disorders and NeonMind’s proprietary psychedelic treatment for weight management, NeonMind’s clinics will also adopt these treatments and serve as future access points to psychedelic modalities, providing important strategic exposure to the psychedelics market.

 

World-Class Specialty Clinics Advisory Board to Guide Build-Out of National Clinic Network

To support a best-in-class integrated services platform and comprehensive set of programs, NeonMind has successfully built an industry-leading advisory board of top-rated clinicians, including  Dr. Sagar Parikh, MD, Dr. Roumen Milev, MD/PhD, and Dr. Gustavo Vazquez, MD/PhD. These board members bring practical and scientific accolades in depression and anxiety disorders and interventional psychiatry which will help further our mission.

All three advisors are highly renowned and considered to be at the forefront of this transformational field with academic influence and significant involvement in national societies and initiatives such as the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the Canadian Biomarker Integration Network for Depression (CAN-BIND). Moreover, they offer vast clinical and research experience from Canada, US and Latin America with hands-on success in setting up and managing interventional psychiatry practices that integrate psychedelics such as ketamine and esketamine. Combined, they have effectively provided thousands of interventional psychiatry treatments to patients.

1 Overall Economic Burden of Mental Health,  www.camh.ca/en/driving-change/the-crisis-is-real/mental-health-statistics

 

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to www.NeonMindBiosciences.com

 

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

 

Investor Relations:

KCSA Strategic Communications

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

 

Media Inquiries:

KCSA Strategic Communications
Annie Graf

neonmind@kcsa.com

Tel: 786-390-2644

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Posted on

Lobe Sciences to Present at the Benzinga Healthcare Small Cap Conference

Lobe Sciences to Present at the Benzinga Healthcare Small Cap Conference

Vancouver, British Columbia–(Newsfile Corp. – September 27, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will present virtually at the Benzinga Healthcare Small Cap Conference taking place September 29-30, 2021.

Philip Young, CEO and Director will begin his presentation at 10:30 A.M. ET on Wednesday, September 29, 2021.

The event is accessible using the following link: https://www.benzinga.com/events/small-cap/healthcare/september-29-track-1/.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Funding to Open New Psychedelic Wellness Clinic Locations, Adding to Leading Footprint

Not for dissemination in the United States or to U.S. newswire services

VANCOUVER, BC September 27, 2021 – Delic Holdings Corp. (“Delic” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has closed its previously announced sale to a single institutional investor for gross proceeds of approximately C$7.0 million in a private placement in the United States (the “Private Placement“).

Pursuant to the Private Placement, the Company issued ‎9,000,000 units of the Company (the “Units“) at a price of C$0.285 per Unit and 15,561,404 pre-funded ‎units of the Company (the “Pre-Funded Units“) at a price of C$0.2849. Each Unit is comprised of one subordinate voting share (a “SV Share“) and one subordinate voting share purchase warrant (a “Warrant“). Each Warrant entitles the holder thereof to purchase one ‎additional SV Share (a “Warrant Share“) at an exercise price of C$0.38 per Warrant Share, subject to ‎‎adjustment, at any time on or prior to 5:00 p.m. ‎‎(Eastern Time) on September 28, 2026. Each Pre-Funded Unit is comprised of one pre-funded subordinate voting share purchase warrant ‎‎(a “Pre-Funded Warrant“) and one Warrant. Each ‎Pre-Funded Warrant entitles the holder thereof to purchase one SV Share (a “Pre-Funded Warrant Share“) at ‎an exercise price of C$0.0001 per Pre-Funded Warrant Share and shall terminate upon exercise in full of ‎the Pre-Funded Warrants. ‎‎

H.C. Wainwright & Co. (“H.C. Wainwright“) acted as the exclusive placement agent for the Private Placement.

H.C. Wainwright received (i) a cash commission of $560,000.01 (equal to 8.0% of the gross proceeds of the Private Placement) and (ii) 1,964,912 compensation warrants (the “Agent Warrants“). Each Agent Warrant entitles the holder thereof to purchase one SV Share at an exercise price of C$0.38 per SV Share at any time on or prior to 5:00 pm (Eastern Time) on September 28, 2026.

The SV Shares, Pre-Funded Warrants and Warrants issued under the Private Placement were qualified by way of a prospectus supplement dated September 24, 2021 under the Company’s short form base shelf prospectus dated September 14, 2021 (the “Prospectus Supplement“) which was filed in the Province of British Columbia. In the United States, the SV Shares, Pre-Funded Warrants and Warrants and the shares issuable upon the exercise of the Pre-Funded Warrants and Warrants were offered on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), and certain other jurisdictions in accordance with applicable securities laws.

The Company intends to use the net proceeds of the Private Placement for expanding clinic foot print, operating costs and acquisitions.

The Private Placement is subject to customary notices and deliveries to the Canadian Securities Exchange.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in Canada in connection with the Private Placement.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities being offered have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of U.S. Persons (within the meaning of Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Delic Corp, Inc.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: use of the net proceeds of the Private Placement; and the receipt of all necessary regulatory and stock exchange approvals for the Private Placement.

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to:

the potential impact of the closing of the Private Placement on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; and compliance ‎with extensive government regulation.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Media Relations Contact

Rich Rodriguez

rich@deliccorp.com

Investor Relations Contact

Daniel Southan-Dwyer

dsd@deliccorp.com

Posted on

1,000 new compounds?

Delix raises $70 million to synthesize psychedelic-inspired drugs

“We are not a one- or two-asset company. We’ve got a large pipeline coming out,” warns David E. Olson, founder of Delix Therapeutics.

The Boston-based startup just raised $70 million in series A financing to develop psychedelic-inspired compounds that are safe enough to take at home.

The company has already synthesized about 1,000 compounds across 8+ classes of psychedelics, with the goal of creating compounds that form synapses between brain cells without inducing hallucinations.

The researchers have found a couple of promising contenders, which are on track to be studied in Phase 1 clinical trials by the end of this year.

PDF of article

Posted on

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

VANCOUVER, BC, Sept. 27, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, introduces its “Desire Project,” a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy.

As part of MINDCURE’s research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder (“HSDD”), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue. According to current estimates, HSDD affects 10% of adult women1 and 14% of premenopausal adult women,2 all reporting that their low desire results in a state of distress. In the U.S. alone, HSDD affects an estimated 9.5 million premenopausal women.3 HSDD is also present in men.

“We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind. Women’s desire issues have not been adequately addressed to date, and we believe that treatment incorporating MDMA and psychotherapy has real promise as it may target those roots of desire in the mind and unlock healing for women lacking desire,” said Kelsey Ramsden, President & CEO, MINDCURE. “MINDCURE has identified a gap in the market, and I think that with the team we have built to execute this project, we can help those seeking improved desire in a new way.”

In clinical trials, MDMA therapy has shown success in helping people heal from Post-Traumatic Stress Disorder (“PTSD”) by working on brain pathways related to fear; it can enhance fear memory extinction, modulate fear memory reconsolidation, and bolster social behavior in animal models. MINDCURE has spent six months designing its forthcoming clinical research program, much of it spent in looking at how MDMA may ease some of these fear factors for women, which play a large role in causing female-related sexual disorders that are not treated by current medications on the market.

“I’m very excited to lead our team and launch a clinical study for the treatment of female Hypoactive Sexual Desire Disorder,” said Dr. Joel Raskin, Chief Medical Officer, MINDCURE. “During my decades as a psychiatrist clinician and researcher, I’ve seen first-hand the limitations of existing treatments. This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder.”

MINDCURE’s “Desire Project” team is comprised of some of the world’s leading researchers in female sexual desire research and psychedelics, including Dr. Jennifer Mitchell, the lead author of the recently published MAPS MDMA-assisted therapy for PTSD study. Dr. Anita Clayton is the Professor and Chair of the Department of Psychiatry and Neurobehavioral Sciences and a Professor of Clinical Obstetrics and Gynecology at the University of Virginia.  Dr. Cindy Meston directs the Female Sexual Psychophysiology Laboratory at the University of Texas in Austin, one of the few laboratories in the world devoted exclusively to the study of women’s sexual health. Dr. Robert Pyke led the Addyi® project, a drug used in treating the symptoms of HSDD through Phases II and III, and has over 100 peer-reviewed publications in the last 18 years. Dr. Sherry Walling is a practicing licensed clinical psychologist with a master’s degree in theology and an emphasis in trauma.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The Company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the treatment of HSDD with MDMA-assisted psychotherapy; potential effects of MDMA on certain fear factors for women; and the execution and potential outcome of the Desire Project.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that MINDCURE will advance wellness worldwide; and the Desire Project will show a successful treatment for HSDD.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results, and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the Desire Project may not be completed as anticipated or at all; MDMA-assisted psychotherapy may not treat HSDD as expected; and results from the Desire Project may not be able to be incorporated into MINDCURE’s products or business as expected. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

1.

https://pubmed.ncbi.nlm.nih.gov/27916394/

2.

https://journals.lww.com/greenjournal/Abstract/2018/05001/Incidence_and_Knowledge_of_Hypoactive_Sexual.649.aspx

3.

Based on an estimate of the number of premenopausal women in the U.S. and the expected number of women affected by HSDD (see footnote 2 above)

SOURCE Mind Cure Health Inc.

For further information: MINDCURE Investor Relations: investors@mindcure.com, 1-888-593-8995; Media Inquiries: Annie Graf / Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com

‍

Posted on

Clearmind Medicine To Fund Second R&D Partnership With Hebrew University’s Technology Transfer Company

Clearmind Medicine To Fund Second R&D Partnership With Hebrew University’s Technology Transfer Company

Toronto, Ontario–(Newsfile Corp. – September 27, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has entered an agreement to fund a second research and development project with Yissum Research Development Company (“Yissum”), the technology transfer company of The Hebrew University of Jerusalem.

The project is consistent with the Company’s focus on developing novel therapies that improve mental health, particularly those relating to addiction, binge behavior and depression.

About Yissum Research Development Corporation

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,875+ patents globally; licensed over 1140+ technologies and has spun out more than 191 companies. Yissum’s business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further information please visit www.yissum.co.il.

About the Hebrew University of Jerusalem

The Hebrew University of Jerusalem is Israel’s first university, formed in 1918 and opened in 1925. Today, there are over 23,000 students enrolled at the University, including undergraduates, master’s degree students, and doctoral candidates. The university has four campuses: Mount Scopus, The Edmond J. Safra (Givat Ram) Campus, and Ein Kerem (in Jerusalem), and Rehovot. Hebrew University Alumni are invited to visit https://new.huji.ac.il.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators”, has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWYO.”

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE“) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. newswire services or dissemination in the United States.

Posted on

Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences

Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences

TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting virtually at two upcoming investor conferences as follows:

Cantor Virtual Global Healthcare Conference, Fireside Chat:
Date: Thursday, September 30, 2021
Time: 2:00PM ET
Webcast: https://wsw.com/webcast/cantor12/clxpf/2262050

The presentation will be webcast live using the link above, and a replay will be available for 90 days.

Benzinga Healthcare Small Cap Conference, Presentation and Panel Discussion:
Date: Thursday, September 30, 2021
Time: 12:15PM ET
Webcast: https://www.benzinga.com/events/small-cap/healthcare/september-30-track-2/

Immediately following the presentation, Mr. Drysdale will participate on a panel, “Addressing Mental Health through Emerging Therapies,” at 12:35PM ET. Both the presentation and panel discussion will be webcast live using the link above.

About Cybin
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding enhanced liquidity, the value of additional capital markets exposure, access to institutional and retail investors, the Company’s new strategic brand messaging campaign, and psychedelic drug development programs to potentially treat mental health disorders. There are numerous risks and uncertainties that could cause actual results and Cybin’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

Investors:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com

Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com

Media:
John Kanakis
Cybin Inc.
John@cybin.com

Source: Cybin Inc.

Posted on

PharmaTher Announces Cad$10 Million Private Placement With Institutional Investors

PharmaTher Announces Cad$10 Million Private Placement With Institutional Investors

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATE

TORONTO, Ontario, September 24, 2021 – PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has entered into a securities purchase agreement with institutional investors for a private placement of its common shares (“Common Shares”) and warrants to purchase common shares (“Warrants”) for gross proceeds of CAD$10 million (the “Private Placement”).  Pursuant to the Private Placement, the Company will issue 15,625,000 Common Shares and Warrants to purchase up to 15,625,000 Common Shares at a purchase price of CAD$0.64 per Common Share and associated Warrant.  Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD$0.80 per Common Share and will be immediately exercisable upon issuance for a period of five years following the issuance date.
​
H.C. Wainwright & Co. is acting as the exclusive placement agent for the Private Placement.

The Company expects to use the net proceeds of the Private Placement for the advancement of its microneedle patch program, its proprietary ketamine product, and for general corporate purposes.

The Private Placement is expected to close on or about September 28, 2021, and is subject to receipt of all applicable approvals and other customary closing conditions, including the approval of the Canadian Securities Exchange.

No securities were offered or sold to Canadian residents in connection with the Private Placement.

The securities being offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws. Accordingly, the securities may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics, such as ketamine, to treat mental health, neurological and pain disorders.  PharmaTher is currently initiating an FDA approved phase 2 clinical study with ketamine to treat Parkinson’s disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.
Learn more at:  PharmaTher.com and follow us on Twitter and LinkedIn.
For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “aim” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the “Company”) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors, including market and other conditions, that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein, including, without limitation, statements relating to the closing of the Private Placement, the gross proceeds to the Company from the Private Placement and the use of proceeds from the Private Placement. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of May 31, 2021 (“MD&A”), dated September 7, 2021, which is available on the Company’s profile at www.sedar.com.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.